Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.08
+0.39000.73%
Post-market: 54.080.00000.00%19:44 EDT
Volume:1.95M
Turnover:105.64M
Market Cap:13.40B
PE:17.01
High:54.68
Open:53.74
Low:53.70
Close:53.69
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.93
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.27
PE(LYR):19.45

Loading ...

Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial

MT Newswires Live
·
May 19

Exelixis partners with Merck on phase 3 colorectal cancer trial combining zanzalintinib, Keytruda Qlex

Reuters
·
May 19

Exelixis Inc - Expects to Initiate Stellar-316 in Mid-2026

THOMSON REUTERS
·
May 19

Exelixis Inc - Merck to Supply Keytruda Qlex for Stellar-316 Trial

THOMSON REUTERS
·
May 19

Exelixis Announces Clinical Development Collaboration With Merck for Phase 3 Stellar-316 Pivotal Trial for Patients With Colorectal Cancer

THOMSON REUTERS
·
May 19

Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion

TIPRANKS
·
May 19

Exelixis director Mary C. Beckerle disposes 7,712 shares for $373,646.4

Reuters
·
May 09

Exelixis Director Maria C. Freire disposes 20,634 shares for $949,164

Reuters
·
May 09

Exelixis director George Poste disposes 60,000 shares for $2.74 million

Reuters
·
May 09

Exelixis to webcast investor conference fireside chats in May

Reuters
·
May 08

Exelixis Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 07

Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives

Simply Wall St.
·
May 07

Exelixis, Inc. : H.c. Wainwright Raises Target Price to $56 From $54

THOMSON REUTERS
·
May 07

Exelixis price target raised to $50 from $49 at Morgan Stanley

TIPRANKS
·
May 07

Exelixis price target raised to $47 from $44 at Stifel

TIPRANKS
·
May 07

Stock Track | Exelixis Soars 9.32% Intraday on Analyst Upgrades and Strong Q1 Earnings

Stock Track
·
May 07

Exelixis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 07

Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says

MT Newswires Live
·
May 07

Stock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings

Stock Track
·
May 06

Goldman Sachs Remains a Buy on Exelixis (EXEL)

TIPRANKS
·
May 06